Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor

Related Experiment Video

Updated: Dec 14, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

521

Beenu Thakral1, Naval Daver2, Zhenya Tang1

  • 1Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA.

Leukemia & Lymphoma
|July 23, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

669
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

435

Related Experiment Videos

Last Updated: Dec 14, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

521
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

669
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

435

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K

Articles linked to this work by shared authors, journal, and citation graph.

Highly diverse MECOM rearrangements uncovered by optical genome mapping and the clinicopathologic features of MECOM-rearranged myeloid neoplasms.

Haematologica·2026

Immunophenotypic, Cytogenetic, and Molecular Characterization of NUP98-Rearranged Pediatric Myeloid Neoplasms.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Chromoanagenesis in Myelodysplastic Syndromes Is Associated With Highly Complex Karyotype, TP53 Disruption, and Dismal Prognosis.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Blinatumomab and ponatinib with central nervous system treatment intensification for adolescents and young adults with Philadelphia-positive B-cell acute lymphoblastic leukemia.

Haematologica·2026

Real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study.

Cytotherapy·2026

Myeloid blast phase of chronic myeloid leukemia with co-occurring t(11;12)(p15;q13)/NUP98::HOXC12: a novel NUP98 fusion partner.

Haematologica·2026

Patients' preferences for accepting risks and uncertainty in AML treatments within European public health care systems: a cross-sectional study in Finland, Italy, and Germany.

Leukemia & lymphoma·2026

Time burden and treatment patterns of patients with newly diagnosed acute myeloid leukemia receiving parenteral hypomethylating agents in combination with venetoclax.

Leukemia & lymphoma·2026

Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.

Leukemia & lymphoma·2026

Zanubrutinib with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory non-germinal center B-cell lymphoma.

Leukemia & lymphoma·2026

Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.

Leukemia & lymphoma·2026

PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study.

Leukemia & lymphoma·2026

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody-Related CRS Without Undermining the Anti-Tumor Efficacy.

Cancer science·2026

Ikaros degradation by Iberdomide correlates with normalization of cytokines in Th cells of patients with systemic lupus erythematosus.

Journal of immunology (Baltimore, Md. : 1950)·2026

The Place of Therapeutic Apheresis in Severe Immune-Related Adverse Events: A Scoping Review of Literature.

Journal of clinical apheresis·2026

[Nontuberculous mycobacterial infections in patients with hematologic diseases].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[The role of MAGIC biomarkers in acute GVHD].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

[Current treatment strategies for diffuse large B-cell lymphoma].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us